EUCTR2011-004011-24-PT进行中（未招募）1 期
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF VEMURAFENIB (RO5185426) ADJUVANT THERAPY IN PATIENTS WITH SURGICALLY RESECTED, CUTANEOUS BRAF-MUTANT MELANOMA AT HIGH RISK FOR RECURRENCE
F. Hoffman-La Roche Ltd.0 个研究点目标入组 498 人开始时间: 2012年12月26日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 498
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Male or female patients age = 18 years
- •Patients with completely resected, histologically confirmed, Stage IIC or Stage III, cutaneous melanoma where the BRAFV600 mutation status of the current primary tumor or involved lymph node is determined to be positive using the cobas® BRAF V600 Mutation Test. Patients with Stage IIIA disease must have at least one lymph node metastasis measuring > 1 mm in diameter
- •ECOG performance status of 0 or 1
- •Life expectancy of at least 5 years
- •Adequate hematologic, liver, and renal function
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 373
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 102
排除标准
- •History of any systemic or local therapy (e.g., chemotherapy, biologic or targeted therapy, hormonal therapy or photodynamic therapy) for the treatment or prevention of melanoma, including interferon-alpha-2b and pegylated interferon-alpha-2b
- •History of radiotherapy for the treatment of melanoma
- •Invasive malignancy other than melanoma at the time of enrollment or within 5 years prior to first study drug administration except for adequately treated (with curative intent) basal or squamous cell carcinoma of the skin, in situ carcinoma of the cervix, in situ ductal adenocarcinoma of the breast, in situ prostate cancer, or limited stage bladder cancer. This requires that the patient pathology evaluation of the screening Papanicolaou (Pap) smear, and of any polyps resected at the screening coloscopy, is negative for invasive malignancy.
- •Known personal history of more than three (>3) adenomatous colorectal polyps or a personal history of adenomatous colorectal polyp(s) > 2 cm in size. This also applies to the screening colonoscopy for select patients.
- •History of or current clinical, radiographic, or pathologic evidence of in-transit metastases, satellite, or microsatellite lesions or recurrent lymph node involvement after resection of a primary melanoma with lymph node involvement at any time in the past
- •History or current radiographic or pathologic evidence of distant metastases
- •History of clinically significant cardiac dysfunction including serious arrhythmias requiring treatment (except for atrial fibrillation and paroxysmal supraventricular tachycardia), history of myocardial infarction within 6 months prior to randomization, and history of congenital long QT syndrome or QTc interval > 450 ms at baseline
- •Current, recent (within 28 days prior to randomization) or planned use of any investigational product outside of this study
研究者
相似试验
进行中（未招募）
1 期
A Study of Gantenerumab in Patients with Mild Alzheimer DiseaseEUCTR2013-003390-95-DKF. Hoffmann-La Roche Ltd1,000
进行中（未招募）
1 期
A Study of Vemurafenib (RO5185426) in Comparison With Placebo as Adjuvant Therapy in Previously Untreated Patients With Adequately Resected Melanoma (BRIM 8)EUCTR2011-004011-24-ITF. HOFFMANN - LA ROCHE LTD.498
进行中（未招募）
1 期
A Phase III study to assess whether etrolizumab is a safe and effective treatment for patients with moderately to severely active Crohn's diseaseEUCTR2014-003824-36-ATF. Hoffmann-La Roche Ltd1,150
尚未招募
3 期
The purpose of this study is to compare the effects, good or bad, of atezolizumab plus trastuzumab emtansine versus placebo plus trastuzumab emtansine in patients with HER2-positive early breast cancer.CancerPACTR202201721209443Hoffmann La Roche1,700
进行中（未招募）
1 期
A Study Evaluating the Efficacy and Safety of GDC-0077 Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Patients with PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer.MedDRA version: 20.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864Breast cancerEUCTR2019-002455-42-FRF. Hoffmann-La Roche Ltd400